Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Understanding the molecular subtype of a cancer is becoming an importance part of the diagnostic process as it helps a doctor better understand a patient’s prognosis, determine the best course of action for treatment and helps researchers devise new, more-efficient, precision therapies.

Image information can be used to predict the molecular classification of patient tumour samples in colour, using state-of-the-art deep learning models in pathology © S:CORT

Colorectal cancer (CRC) currently has four known molecular subtypes which are identified on the basis of its RNA expression profile, using RNA analysis. But the process of RNA analysis is costly, technically challenging and it requires a specialist to interpret data to determine the subtype. In order to more efficiently and cheaply determine the molecular subtype of a patient’s CRC, there is a need to use more easily-acquired data on a tumour and categorise its subtype based on an automated technique.

One prevalent source of data in cancer diagnostics is images, such as histological images of the microscopic anatomy of a cancer. Almost all CRC patients already have a sample of their tumour inspected by a pathologist as part of their standard care.

A new paper published by Dr Korsuk Sirinukunwattana, Dr Enric Domingo, Prof Viktor H Koelzer & Prof Jens Rittscher from the Stratification in Colorectal Cancer consortium (S:CORT), has demonstrated the potential for using these images to determine molecular subtype.

Through the training of a deep-learning neural network, using over 1,000 tumour samples, the team discovered that AI could be trained to distinguish between the four molecular subtypes using images alone.

Usually, histological images are a modest indicator of how colorectal cancers have progressed, and there is currently no way to determine the molecular subtype of a tumour by the human eye alone, without doing a gene profile on tumour samples. However, this new study demonstrates that technology can be trained to identify the minute morpho-molecular differences between molecular subtypes.

This new concept, called Image-based Consensus Molecular Subtyping (imCMS), will allow images to be interpreted through association of tile-level predictions with morphology, molecular features and outcome data.

Furthermore, this study also demonstrated that AI is able to classify the molecular subtype of samples that were previously unclassifiable by the standard process of RNA expression profiling. It also provides information for the spatial distribution of each subtype within a tumour.

This AI technology will have huge implications on the standardisation of classifying molecular subtypes of CRC.

More details can be found on the CRUK Oxford Centre website

Similar stories

Researchers develop easy-to-deploy federated learning system that safeguards patient data

The technique, which builds on recent advances in decentralised machine learning, uses inexpensive pre-programmed micro-computers, making it easy to deploy in hospitals and cheap to scale up.

Festive Science Image Competition Winners

Winners of the Medical Research Foundation's second Festive Science Image Competition, run in partnership with the Medical Research Council (MRC), have been announced today.

Robert Watson Awarded ACP McElwain and Presidents Prize

Dr Robert Watson has won one of three McElwain and President's Prizes from the Association of Cancer Physicians for his DPhil work undertaken with Professor Ben Fairfax.

Prof Anna Schuh launches first private specialised haematology clinic and laboratory in sub-Saharan Africa.

SerenOx Africa aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility will also aim to provide early cancer detection for high-risk patients.